Assenagon Asset Management S.A. Has $441,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assenagon Asset Management S.A. decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 90.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,216 shares of the company’s stock after selling 146,183 shares during the period. Assenagon Asset Management S.A.’s holdings in Amphastar Pharmaceuticals were worth $441,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after buying an additional 493 shares during the last quarter. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after buying an additional 871 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at approximately $38,000. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after buying an additional 424 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock valued at $43,000 after buying an additional 348 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $32.33.

Amphastar Pharmaceuticals Stock Down 1.1%

NASDAQ:AMPH opened at $25.34 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 9.18, a price-to-earnings-growth ratio of 6.60 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The stock’s 50 day moving average price is $24.76 and its two-hundred day moving average price is $30.42.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.